GlassScriptPhysician profile
Brian Thomas Odonoghue
NPI 1962402842
$5,552.05
in general payments reported to CMS, 2019-2025
38 companies · $1,274 in 2025
The $1,274 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $307 · 2021: $697 · 2022: $932 · 2023: $1,029 · 2024: $1,004 · 2025: $1,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,306.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,008.40 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $520.60 | 2021-2025 | |
| Amgen INC. | $509.15 | 2019-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $500.45 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $334.87 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $314.64 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $292.60 | 2019-2025 | Jardiance, Cyltezo |
| Lilly USA, LLC | $279.24 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $202.32 | 2019-2025 | |
| Glaxosmithkline, LLC. | $152.93 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amarin Pharma, INC. | $147.50 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $143.91 | 2022 | |
| Phathom Pharmaceuticals, INC. | $107.01 | 2024-2025 | Voquezna |
| Esperion Therapeutics, INC. | $82.27 | 2020-2021 | |
| Astellas Pharma US INC | $78.37 | 2019-2025 | Veozah |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Odonoghue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.